Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
ONGENTYS: selected primary-label renal guidance and limits
Product / population
Adult oral ONGENTYS as adjunct to levodopa/carbidopa; renal instruction does not replace the full Parkinson regimen review.
Renal method
CrCl, mL/min; ESRD avoidance below 15
Source revision
11/2025
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
ONGENTYS: source applicability and renal evidence limits
CrCl <15: avoid. Do not infer a dialysis regimen. The RX mirror is not independent corroboration of the matched label.
What to reconcile: Severe impairment: monitor adverse effects and stop for intolerance.
DailyMed / product prescribing information · Adult oral ONGENTYS as adjunct to levodopa/carbidopa; renal instruction does not replace the full Parkinson regimen review.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding
CrCl <15: avoid. Do not infer a dialysis regimen.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 8.6
No dose adjustment is required in mild, moderate or severe impairment. Severe impairment requires adverse-reaction monitoring because exposure may increase; discontinue if tolerability problems develop. Avoid use in ESRD (CrCl <15 mL/min). A no-adjustment instruction above that restriction is not proof that every severe-renal population was directly studied.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
